Description:
<p><b>L-Ornithine</b> — L-ornithine (L-Orn) is an endogenous, non-proteinogenic α-amino acid and central intermediate of the urea cycle. It is classified as an amino-acid metabolite and nutritional supplement rather than an established anticancer drug. L-Ornithine is generated primarily from L-arginine by arginase and can be metabolized toward citrulline and urea-cycle flux, polyamines through ornithine decarboxylase, or glutamate/proline through ornithine aminotransferase. Supplemental forms commonly include free L-ornithine and L-ornithine hydrochloride. Of particular relevance to cancer, ornithine is a substrate for pathways that can support tumor proliferation; therefore, supplemental L-ornithine should not be interpreted as intrinsically anticancer.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>ODC1/polyamine pathway substrate — ornithine is decarboxylated by ornithine decarboxylase 1 (ODC1) to putrescine, which is subsequently converted to spermidine and spermine. This pathway is frequently elevated in cancer and can support proliferation, translation, chromatin regulation, stress adaptation, and tumor-associated immunosuppression.</li>
<li>Urea-cycle and ammonia metabolism — ornithine accepts carbamoyl phosphate through ornithine transcarbamylase to form citrulline, supporting hepatic nitrogen disposal and urea production.</li>
<li>OAT/proline/glutamate metabolic branch — ornithine aminotransferase converts ornithine toward glutamate-semialdehyde, linking ornithine to glutamate, proline, and anabolic metabolism. OAT dependence occurs in selected cancers, particularly hepatocellular carcinoma.</li>
<li>Arginine-ornithine metabolic axis — arginase converts arginine to ornithine and urea. Increased ARG1/ARG2 activity in tumors and suppressive myeloid cells can simultaneously deplete immunologically important arginine and increase substrate availability for polyamine and proline metabolism.</li>
<li>Stress, fatigue, and metabolic effects — human supplementation studies report effects on fatigue and selected stress-related endpoints, but these findings are not established cancer mechanisms and appear independent of a consistent direct endocrine effect.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral L-ornithine is systemically absorbed. In a human oral-load study, approximately 6.4 g ornithine administered as ornithine hydrochloride produced a plasma ornithine peak of approximately 541 µmol/L at 60–75 minutes. It is rapidly integrated into amino-acid, urea-cycle, and tissue metabolism, so plasma exposure does not directly predict tumor ornithine flux. No tumor-selective delivery or clinically validated anticancer exposure has been established.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> A conventional anticancer concentration comparison is not appropriate because L-ornithine is primarily a physiological metabolic substrate rather than a direct cytotoxic agent. Cancer research more commonly inhibits ODC1, polyamine transport, OAT, or related arginine/ornithine metabolism rather than exposing tumors to high concentrations of L-ornithine. Consequently, there is no validated systemic L-ornithine concentration associated with anticancer efficacy.</p>
<p><b>Clinical evidence status:</b> No established clinical evidence supports L-ornithine supplementation as a cancer treatment. Human randomized trials exist for fatigue, stress, exercise, and nutritional applications, but not for anticancer efficacy. Oral supplementation appears generally well tolerated in healthy adults; a 2025 systematic review identified gastrointestinal symptoms as the principal adverse-effect category and estimated a no-observed-adverse-effect level of approximately 12 g/day as L-ornithine hydrochloride. From an oncology perspective, the evidence is biochemical/preclinical and raises a potential concern that additional ornithine could feed polyamine synthesis in tumors with active ODC1 rather than inhibit it.</p>
<h3>L-Ornithine Mechanistic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ODC1 and polyamine synthesis</td>
<td>↑ polyamine precursor availability (context-dependent)</td>
<td>↑ physiological polyamine precursor availability</td>
<td>Putrescine, spermidine and spermine synthesis</td>
<td>Most important cancer-related consequence. High ODC1/polyamine activity is common in malignancy and supports proliferation. Anticancer therapy generally seeks to ↓ this pathway using ODC1 or polyamine-transport inhibition rather than supplementing ornithine.</td>
</tr>
<tr>
<td>2</td>
<td>Cell proliferation through polyamines</td>
<td>↑ proliferative support (context-dependent)</td>
<td>↑ growth and repair support</td>
<td>Supports nucleic-acid, translation and chromatin functions</td>
<td>Ornithine itself is not an oncogene, but increased substrate availability can contribute to polyamine production when ODC1 activity is elevated.</td>
</tr>
<tr>
<td>3</td>
<td>Urea cycle and ammonia disposal</td>
<td>↔ or altered (tumor-dependent)</td>
<td>↑ urea-cycle substrate flux</td>
<td>Nitrogen disposal and citrulline formation</td>
<td>Core physiological function, particularly in liver. Cancer frequently rewires individual urea-cycle enzymes, so effects within tumors are heterogeneous.</td>
</tr>
<tr>
<td>4</td>
<td>OAT glutamate and proline metabolism</td>
<td>↑ substrate availability (model-dependent)</td>
<td>↑ physiological amino-acid interconversion</td>
<td>Glutamate-semialdehyde, glutamate and proline metabolism</td>
<td>OAT can support anabolic metabolism in selected cancers. The evidence supports targeting OAT in some tumors but does not establish supplemental ornithine as an anticancer intervention.</td>
</tr>
<tr>
<td>5</td>
<td>Arginase ornithine axis</td>
<td>↑ downstream ornithine metabolism (context-dependent)</td>
<td>↑ normal arginine catabolism</td>
<td>Links arginine depletion with ornithine production</td>
<td>ARG1 and ARG2 can be elevated in cancer and tumor-associated myeloid cells. Arginase-mediated arginine depletion can suppress T-cell function while generated ornithine enters polyamine and proline pathways. Exogenous ornithine does not itself activate arginase.</td>
</tr>
<tr>
<td>6</td>
<td>Tumor immune microenvironment through polyamines</td>
<td>↑ immunosuppressive potential (indirect, context-dependent)</td>
<td>↔</td>
<td>Polyamine-dependent immune regulation</td>
<td>Polyamine accumulation can promote suppressive myeloid phenotypes and other tumor-immune adaptations. Evidence concerns polyamine metabolism rather than direct L-ornithine supplementation.</td>
</tr>
<tr>
<td>7</td>
<td>Clinical Translation Constraint</td>
<td>Anticancer benefit not established</td>
<td>Oral supplementation generally tolerated</td>
<td>No validated oncology indication</td>
<td>No cancer RCT evidence for L-ornithine supplementation. Physiological metabolism and rapid pathway integration limit interpretation as a direct anticancer agent; there is a theoretical concern that supplementation could increase substrate supply to tumor polyamine metabolism.</td>
</tr>
</tbody>
</table>